Correction: Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE) (Trials, (2022), 23, 1, (583), 10.1186/s13063-022-06533-0)

Tania A. Smith; Carlos Hoyo-Vadillo; Akosua Agyeman Adom; Liliana Favari-Perozzi; Silke Gastine; Hakim Moulay Dehbi; Beatriz Villegas-Lara; Eduardo Mateos; Yessica Sara Pérez González; Maria D. Navarro-Gualito; Alejandra S. Cruz-Carbajal; Miguel A. Cortes-Vazquez; Carolina Bekker-Méndez; Charmina Aguirre-Alvarado; Gisela Aguirre-Gil; Lucero Delgado-Pastelin; Andrew Owen; David Lowe; Joseph Standing; Jorge Escobedo

doi:10.1186/s13063-023-07364-3

Correction: Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE) (Trials, (2022), 23, 1, (583), 10.1186/s13063-022-06533-0)

Tania A. Smith, Carlos Hoyo-Vadillo, Akosua Agyeman Adom, Liliana Favari-Perozzi, Silke Gastine, Hakim Moulay Dehbi, Beatriz Villegas-Lara, Eduardo Mateos, Yessica Sara Pérez González, Maria D. Navarro-Gualito, Alejandra S. Cruz-Carbajal, Miguel A. Cortes-Vazquez, Carolina Bekker-Méndez, Charmina Aguirre-Alvarado, Gisela Aguirre-Gil, Lucero Delgado-Pastelin, Andrew Owen, David Lowe, Joseph Standing, Jorge Escobedo

Research output: Contribution to journal › Comment/debate

Abstract

The original publication of this article [1] erroneously contained "2X2 design" in the title whilst the study itself did not include a 2 × 2 design. The original article has been updated.

Original language	English
Article number	347
Journal	Trials
Volume	24
Issue number	1
DOIs	https://doi.org/10.1186/s13063-023-07364-3
State	Published - Dec 2023
Externally published	Yes

Access to Document

10.1186/s13063-023-07364-3

Fingerprint

Dive into the research topics of 'Correction: Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE) (Trials, (2022), 23, 1, (583), 10.1186/s13063-022-06533-0)'. Together they form a unique fingerprint.

Cite this

Smith, T. A., Hoyo-Vadillo, C., Adom, A. A., Favari-Perozzi, L., Gastine, S., Dehbi, H. M., Villegas-Lara, B., Mateos, E., González, Y. S. P., Navarro-Gualito, M. D., Cruz-Carbajal, A. S., Cortes-Vazquez, M. A., Bekker-Méndez, C., Aguirre-Alvarado, C., Aguirre-Gil, G., Delgado-Pastelin, L., Owen, A., Lowe, D., Standing, J., & Escobedo, J. (2023). Correction: Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE) (Trials, (2022), 23, 1, (583), 10.1186/s13063-022-06533-0). Trials, 24(1), Article 347. https://doi.org/10.1186/s13063-023-07364-3

Smith, Tania A. ; Hoyo-Vadillo, Carlos ; Adom, Akosua Agyeman et al. / Correction : Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE) (Trials, (2022), 23, 1, (583), 10.1186/s13063-022-06533-0). In: Trials. 2023 ; Vol. 24, No. 1.

@article{0ae487e270114f59a5aaf049fc93e009,

title = "Correction: Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE) (Trials, (2022), 23, 1, (583), 10.1186/s13063-022-06533-0)",

abstract = "The original publication of this article [1] erroneously contained {"}2X2 design{"} in the title whilst the study itself did not include a 2 × 2 design. The original article has been updated.",

author = "Smith, {Tania A.} and Carlos Hoyo-Vadillo and Adom, {Akosua Agyeman} and Liliana Favari-Perozzi and Silke Gastine and Dehbi, {Hakim Moulay} and Beatriz Villegas-Lara and Eduardo Mateos and Gonz{\'a}lez, {Yessica Sara P{\'e}rez} and Navarro-Gualito, {Maria D.} and Cruz-Carbajal, {Alejandra S.} and Cortes-Vazquez, {Miguel A.} and Carolina Bekker-M{\'e}ndez and Charmina Aguirre-Alvarado and Gisela Aguirre-Gil and Lucero Delgado-Pastelin and Andrew Owen and David Lowe and Joseph Standing and Jorge Escobedo",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2023.",

year = "2023",

month = dec,

doi = "10.1186/s13063-023-07364-3",

language = "Ingl{\'e}s",

volume = "24",

journal = "Trials",

issn = "1745-6215",

number = "1",

}

Smith, TA, Hoyo-Vadillo, C, Adom, AA, Favari-Perozzi, L, Gastine, S, Dehbi, HM, Villegas-Lara, B, Mateos, E, González, YSP, Navarro-Gualito, MD, Cruz-Carbajal, AS, Cortes-Vazquez, MA, Bekker-Méndez, C, Aguirre-Alvarado, C, Aguirre-Gil, G, Delgado-Pastelin, L, Owen, A, Lowe, D, Standing, J & Escobedo, J 2023, 'Correction: Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE) (Trials, (2022), 23, 1, (583), 10.1186/s13063-022-06533-0)', Trials, vol. 24, no. 1, 347. https://doi.org/10.1186/s13063-023-07364-3

Correction: Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE) (Trials, (2022), 23, 1, (583), 10.1186/s13063-022-06533-0). / Smith, Tania A.; Hoyo-Vadillo, Carlos; Adom, Akosua Agyeman et al.
In: Trials, Vol. 24, No. 1, 347, 12.2023.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction

T2 - Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE) (Trials, (2022), 23, 1, (583), 10.1186/s13063-022-06533-0)

AU - Smith, Tania A.

AU - Hoyo-Vadillo, Carlos

AU - Adom, Akosua Agyeman

AU - Favari-Perozzi, Liliana

AU - Gastine, Silke

AU - Dehbi, Hakim Moulay

AU - Villegas-Lara, Beatriz

AU - Mateos, Eduardo

AU - González, Yessica Sara Pérez

AU - Navarro-Gualito, Maria D.

AU - Cruz-Carbajal, Alejandra S.

AU - Cortes-Vazquez, Miguel A.

AU - Bekker-Méndez, Carolina

AU - Aguirre-Alvarado, Charmina

AU - Aguirre-Gil, Gisela

AU - Delgado-Pastelin, Lucero

AU - Owen, Andrew

AU - Lowe, David

AU - Standing, Joseph

AU - Escobedo, Jorge

PY - 2023/12

Y1 - 2023/12

N2 - The original publication of this article [1] erroneously contained "2X2 design" in the title whilst the study itself did not include a 2 × 2 design. The original article has been updated.

AB - The original publication of this article [1] erroneously contained "2X2 design" in the title whilst the study itself did not include a 2 × 2 design. The original article has been updated.

UR - http://www.scopus.com/inward/record.url?scp=85159793539&partnerID=8YFLogxK

U2 - 10.1186/s13063-023-07364-3

DO - 10.1186/s13063-023-07364-3

M3 - Comentario/Debate

C2 - 37218017

AN - SCOPUS:85159793539

SN - 1745-6215

VL - 24

JO - Trials

JF - Trials

IS - 1

M1 - 347

ER -

Smith TA, Hoyo-Vadillo C, Adom AA, Favari-Perozzi L, Gastine S, Dehbi HM et al. Correction: Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE) (Trials, (2022), 23, 1, (583), 10.1186/s13063-022-06533-0). Trials. 2023 Dec;24(1):347. doi: 10.1186/s13063-023-07364-3

Correction: Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE) (Trials, (2022), 23, 1, (583), 10.1186/s13063-022-06533-0)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this